Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies

Abstract

The immune checkpoint blockade therapy has completely transformed cancer treatment modalities because of its unprecedented and durable clinical responses in various cancers. With the increasing use of immune checkpoint blockades in clinical practice, a large number of patients develop acquired resistance. However, the knowledge about acquired resistance to immune checkpoint blockades is limited and poorly summarized. In this review, we clarify the principal elements of acquired resistance to immune checkpoint blockades. The definition of acquired resistance is heterogeneous among groups or societies, but the expert consensus of The Society for Immunotherapy of Cancer can be referred. Oligo-progression is the main pattern of acquired resistance. Acquired resistance can be derived from the selection of resistant cancer cell clones that exist in the tumor mass before therapeutic intervention or gradual acquisition in the sensitive cancer cells. Specifically, tumor intrinsic mechanisms include neoantigen depletion, defects in antigen presentation machinery, aberrations of interferon signaling, tumor-induced exclusion/immunosuppression, and tumor cell plasticity. Tumor extrinsic mechanisms include upregulation of other immune checkpoints. Presently, a set of treatment modalities is applied to patients with similar clinical characteristics or resistance mechanisms for overcoming acquired resistance, and hence, further research is required.

Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy

“…Apart from their role in tumor development and immune escape, the reprogramming of tumor cells’ metabolism influences immune cell metabolism ( 118 ). Tryptophan (Trp) metabolism in T cells is mediated by tumor cells through an elevated level of indoleamine 2,3-dioxygenase (IDO) expression, which converts Trp to kynurenine (Kyn) ( 119 ). Lack of Trp inhibits CTL activation, while abnormal accumulation of Kyn recruits Treg to suppress effector T-cell function ( 120 , 121 ).…”

Editorial: Immune modulation in tumor microenvironment: New perspectives for cancer immunotherapy

“…Tumor cells suppress the immune environment through different mechanisms ( Zhou et al, 2021 ). Recently, diversified therapeutic strategies have been used to restore host immunity and enhance the sensitivity to immunotherapy ( Binnewies et al, 2018 ; Hu et al, 2022 ).…”

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data

“…Immune checkpoint inhibitors (ICIs) aim to disrupt the interaction between surface molecules responsible for immune exhaustion, which drives immune escape by cancer cells. 1 , 2 , 3 , 4 , 5 , 6 These molecules, such as programmed cell death receptor‐1 (PD‐1), cytotoxic T lymphocyte‐associated molecule‐4 (CTLA‐4) or lymphocyte‐activation gene 3 (LAG‐3), are expressed by tumor‐infiltrating T lymphocytes and, upon interaction with cognate ligands expressed by tumor cells and microenvironment, restrain immune rejection of cancer.…”